Your browser doesn't support javascript.
At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant.
Singanallur, Nagendrakumar B; van Vuren, Petrus Jansen; McAuley, Alexander J; Bruce, Matthew P; Kuiper, Michael J; Gwini, Stella M; Riddell, Shane; Goldie, Sarah; Drew, Trevor W; Blasdell, Kim R; Tachedjian, Mary; Mangalaganesh, Shruthi; Chahal, Simran; Caly, Leon; Druce, Julian D; Juno, Jennifer A; Kent, Stephen J; Wheatley, Adam K; Vasan, Seshadri S.
  • Singanallur NB; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia.
  • van Vuren PJ; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia.
  • McAuley AJ; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia.
  • Bruce MP; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia.
  • Kuiper MJ; Data61, Commonwealth Scientific and Industrial Research Organisation (CSIRO), Docklands, VIC, Australia.
  • Gwini SM; University Hospital Geelong, Barwon Health, Geelong, VIC, Australia.
  • Riddell S; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia.
  • Goldie S; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia.
  • Drew TW; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia.
  • Blasdell KR; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia.
  • Tachedjian M; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia.
  • Mangalaganesh S; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia.
  • Chahal S; Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
  • Caly L; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia.
  • Druce JD; Victorian Infectious Diseases Reference Laboratory (VIDRL), The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Juno JA; Victorian Infectious Diseases Reference Laboratory (VIDRL), The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Kent SJ; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Wheatley AK; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Vasan SS; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
Front Immunol ; 13: 883612, 2022.
Article in English | MEDLINE | ID: covidwho-1875414
ABSTRACT
Plasma samples taken at different time points from donors who received either AstraZeneca (Vaxzevria) or Pfizer (Comirnaty) or Moderna (Spikevax) coronavirus disease-19 (COVID-19) vaccine were assessed in virus neutralization assays against Delta and Omicron variants of concern and a reference isolate (VIC31). With the Pfizer vaccine there was 6-8-fold reduction in 50% neutralizing antibody titres (NT50) against Delta and VIC31 at 6 months compared to 2 weeks after the second dose; followed by 25-fold increase at 2 weeks after the third dose. Neutralisation of Omicron was only consistently observed 2 weeks after the third dose, with most samples having titres below the limit of detection at earlier timepoints. Moderna results were similar to Pfizer at 2 weeks after the second dose, while the titres for AstraZeneca samples derived from older donors were 7-fold lower against VIC31 and below the limit of detection against Delta and Omicron. Age and gender were not found to significantly impact our results. These findings indicate that vaccine matching may be needed, and that at least a third dose of these vaccines is necessary to generate sufficient neutralising antibodies against emerging variants of concern, especially Omicron, amidst the challenges of ensuring vaccine equity worldwide.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.883612

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.883612